PLA2R1 and membranous glomerulonephritis: Since it has been clarified that autoantibodies against PLA2R or THSD7A are present in many patients with membranous nephropathy, rituximab is expected to suppress the actions of B cells and reduce the production of autoantibodies against PLA2R or THSD7A, the possible causes of disorders, to exert its action for a long period.